C07D 487/20
Spiro-condensed systems
C07D487/20 (Spiro-condensed systems) appears on 123 US grants and 184 published applications in this corpus.
Search patents in C07D- Granted patents
- 123
- Published applications
- 184
- Assignees
- 92
- Inventors
- 570
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 1 | 1 |
| 2004 | 0 | 1 |
| 2005 | 2 | 2 |
| 2006 | 2 | 2 |
| 2007 | 1 | 0 |
| 2008 | 1 | 3 |
| 2009 | 0 | 1 |
| 2010 | 1 | 1 |
| 2011 | 2 | 7 |
| 2012 | 0 | 6 |
| 2013 | 7 | 12 |
| 2014 | 14 | 10 |
| 2015 | 6 | 15 |
| 2016 | 9 | 13 |
| 2017 | 8 | 12 |
| 2018 | 8 | 8 |
| 2019 | 9 | 8 |
| 2020 | 6 | 11 |
| 2021 | 10 | 9 |
| 2022 | 7 | 11 |
| 2023 | 4 | 19 |
| 2024 | 7 | 10 |
| 2025 | 8 | 15 |
| 2026 | 6 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- High-activity Wnt pathway inhibitor compound12 May 2026US 12,622,917 B2Adlai Nortye Biopharma Co., Ltd.
- Tetrahydro-spiroindoline-pyrrolopyrrole-triones inhibitors of the NRF2-β-TrCP interaction for use in the treatment of fatty liver disease31 Mar 2026US 12,590,100 B2
- SMARCA inhibitors and uses thereof10 Mar 2026US 12,569,485 B2Kymera Therapeutics, Inc.
- Substituted 1′,2′-dihydro-3′h-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c] [1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors3 Mar 2026US 12,565,502 B2Pharmacosmos Holding A/S
- Dispiropyrrolidine derivatives10 Feb 2026US 12,545,685 B2Daiichi Sankyo Company, Limited
- Compounds and methods of treating cancers1 Oct 2026US 2026/0297081 A1Cullgen Inc.
- Composition for preventing or treating retinal diseases23 Jul 2026US 2026/0209188 A1Seoul National University Hospital
- 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp5316 Jul 2026US 2026/0200932 A1Adamed Pharma S.A.
- Crbn ligand, preparation method therefor, and application9 Jul 2026US 2026/0191970 A1Shenzhen Zhongge Biological Technology Co., Ltd.
- Cdk inhibitors and methods of use thereof9 Jul 2026US 2026/0193248 A1Relay Therapeutics, Inc.
Most cited
By later US patents
- 2'-4'-h alo-1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spirocyclopentane-1,7' (8'H)-3H! imidazo2,1-b!purin!-4' (5'H)-ones54US 5,824,683 ASchering Corporation · 1998
- CDK inhibitors51US 8,598,186 B2G1 Therapeutics, Inc. · 2013
- CDK inhibitors48US 8,598,197 B2G1 Therapeutics, Inc. · 2013
- CDK inhibitors46US 8,691,830 B2G1 Therapeutics, Inc. · 2014
- CDK inhibitors44US 8,822,683 B2G1 Therapeutics, Inc. · 2014